New Drug Offers Hope in Fight Against Deadly Pancreatic Cancer
A new KRAS inhibitor drug, daraxonrasib, shows promising results in clinical trials for pancreatic cancer, offering hope for improved survival and quality of life for patients with this deadly disease, with the potential for faster approval due to government designations.